Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Public ClinicalTrials.gov record NCT04164199. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies
Study identification
- NCT ID
- NCT04164199
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- BeOne Medicines
- Industry
- Enrollment
- 404 participants
Conditions and interventions
Conditions
Interventions
- BAT1706 Drug
- BGB-15025 Drug
- BGB-A445 Drug
- Fruquintinib Drug
- LBL-007 Drug
- Lenvatinib Drug
- Ociperlimab Drug
- Pamiparib Drug
- Sitravatinib Drug
- Surzebiclimab Drug
- Temozolomide Drug
- Tislelizumab Drug
- Zanidatamab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2019
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
- Last update posted
- Apr 22, 2026
2019 – 2026
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mount Sinai Comprehensive Cancer Center | Miami | Florida | 33140-2840 | — |
| Memorial Sloan Kettering Cancer Center Mskcc | New York | New York | 10065-6800 | — |
| Tennessee Oncology, Pllc Nashville | Nashville | Tennessee | 37203 | — |
| Baylor Research Institute | Dallas | Texas | 75246-2079 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04164199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04164199 live on ClinicalTrials.gov.